Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 3993129A

Next Previous
Search
Drug Profile

GSK 3993129A

Alternative Names: Cytomegalovirus-recombinant-protein-subunit-vaccine-GSK; GSK-3993129; GSK-3993129A; Pentamer-adjuvant-vaccine-GSK

Latest Information Update: 27 Jul 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK
  • Class Cytomegalovirus vaccines; Glycoproteins; Subunit vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cytomegalovirus infections

Most Recent Events

  • 15 Feb 2022 Phase-II clinical trials in Cytomegalovirus infections (Prevention, In adults, In adolescents) in USA (IM) (GSK pipeline, February 2022)
  • 27 Oct 2021 GlaxoSmithKline plans to initiate a phase I/II trial for Cytomegalovirus infections (In adults, Prevention) (NCT05089630)
  • 14 Oct 2021 Phase I in Cytomegalovirus infections (In adults, Prevention) (IM) in USA (NCT05089630)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top